IQVIA Holdings Inc. (IQV) stock
IQVNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 9/3016% above fair value
$257.60−7.13 (-2.69%)
Close on Nov 17, 2026Market cap $42.45BP/E 31.3Yield –
Iqvia EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Iqvia's EPS for the twelve months ending Sep 30, 2026 was $8.23, up 12.9% year over year. For fiscal 2025 it was $7.84, up 4.7% from the year before. Over ten years it grew 9.8% a year on average. The highest annual figure on record is $7.84 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.84 | +4.7% |
| FY2024 | Dec 31, 2024 | $7.49 | +2.7% |
| FY2023 | Dec 31, 2023 | $7.29 | +27.4% |
| FY2022 | Dec 31, 2022 | $5.72 | +15.6% |
| FY2021 | Dec 31, 2021 | $4.95 | +246.2% |
| FY2020 | Dec 31, 2020 | $1.43 | +49.0% |
| FY2019 | Dec 31, 2019 | $0.96 | -22.6% |
| FY2018 | Dec 31, 2018 | $1.24 | -78.4% |
| FY2017 | Dec 31, 2017 | $5.74 | +1121.3% |
| FY2016 | Dec 31, 2016 | $0.47 | -84.7% |
| FY2015 | Dec 31, 2015 | $3.08 | +13.2% |
| FY2014 | Dec 31, 2014 | $2.72 | +53.7% |
| FY2013 | Dec 31, 2013 | $1.77 | +17.2% |
| FY2012 | Dec 31, 2012 | $1.51 | -26.3% |
| FY2011 | Dec 31, 2011 | $2.05 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.10 | +8.8% |
| Q2 FY2026 | Jun 30, 2026 | $1.53 | -0.6% |
| Q1 FY2026 | Mar 31, 2026 | $1.61 | +15.0% |
| Q4 FY2025 | Dec 31, 2025 | $2.99 | +23.6% |
| Q3 FY2025 | Sep 30, 2025 | $1.93 | +24.5% |
| Q2 FY2025 | Jun 30, 2025 | $1.54 | -21.8% |
| Q1 FY2025 | Mar 31, 2025 | $1.40 | -10.3% |
| Q4 FY2024 | Dec 31, 2024 | $2.42 | -4.7% |
| Q3 FY2024 | Sep 30, 2024 | $1.55 | -4.9% |
| Q2 FY2024 | Jun 30, 2024 | $1.97 | +23.9% |
| Q1 FY2024 | Mar 31, 2024 | $1.56 | +2.0% |
| Q4 FY2023 | Dec 31, 2023 | $2.54 | +111.7% |
| Q3 FY2023 | Sep 30, 2023 | $1.63 | +9.4% |
| Q2 FY2023 | Jun 30, 2023 | $1.59 | +18.7% |
| Q1 FY2023 | Mar 31, 2023 | $1.53 | -8.9% |
| Q4 FY2022 | Dec 31, 2022 | $1.20 | -26.4% |
| Q3 FY2022 | Sep 30, 2022 | $1.49 | +11.2% |
| Q2 FY2022 | Jun 30, 2022 | $1.34 | +48.9% |
| Q1 FY2022 | Mar 31, 2022 | $1.68 | +54.1% |
| Q4 FY2021 | Dec 31, 2021 | $1.63 | +167.2% |
| Q3 FY2021 | Sep 30, 2021 | $1.34 | +157.7% |
| Q2 FY2021 | Jun 30, 2021 | $0.90 | – |
| Q1 FY2021 | Mar 31, 2021 | $1.09 | +159.5% |
| Q4 FY2020 | Dec 31, 2020 | $0.61 | +577.8% |
| Q3 FY2020 | Sep 30, 2020 | $0.52 | +79.3% |
| Q2 FY2020 | Jun 30, 2020 | -$0.12 | -140.0% |
| Q1 FY2020 | Mar 31, 2020 | $0.42 | +44.8% |
| Q4 FY2019 | Dec 31, 2019 | $0.09 | -73.5% |
| Q3 FY2019 | Sep 30, 2019 | $0.29 | 0.0% |
| Q2 FY2019 | Jun 30, 2019 | $0.30 | +3.4% |
| Q1 FY2019 | Mar 31, 2019 | $0.29 | -9.4% |
| Q4 FY2018 | Dec 31, 2018 | $0.34 | -92.9% |
| Q3 FY2018 | Sep 30, 2018 | $0.29 | -27.5% |
| Q2 FY2018 | Jun 30, 2018 | $0.29 | +3.6% |
| Q1 FY2018 | Mar 31, 2018 | $0.32 | -25.6% |
| Q4 FY2017 | Dec 31, 2017 | $4.79 | – |
| Q3 FY2017 | Sep 30, 2017 | $0.40 | – |
| Q2 FY2017 | Jun 30, 2017 | $0.28 | – |
| Q1 FY2017 | Mar 31, 2017 | $0.43 | – |
| Q4 FY2016 | Dec 31, 2016 | -$0.74 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?